Corbus Pharmaceuticals CRB-913 Obesity Drug Completes Patient Enrollment in CANYON-1 Phase 1b Trial

Key Takeaways

• Corbus Pharmaceuticals has completed patient enrollment for its CANYON-1 Phase 1b study of CRB-913, an oral obesity treatment, with 240 participants
• Early Phase 1a data showed nearly 3% weight loss in just 14 days, demonstrating potential efficacy of this non-incretin approach
• Results from the 16-week dose-finding study are expected in summer 2026, potentially advancing a new class of oral obesity medications

---

Corbus Pharmaceuticals Advances Novel Obesity Treatment

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced on April 14, 2026, that the last patient has completed their first visit in the CANYON-1 Phase 1b clinical trial evaluating CRB-913 for obesity treatment. The Norwood, Massachusetts-based clinical-stage company is now on track to complete this pivotal 16-week, dose-finding study by summer 2026.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Promising Early Results Drive Development Forward

The Phase 1b trial builds upon encouraging Phase 1a findings that demonstrated nearly 3% weight loss within just 14 days in individuals with obesity. This rapid onset of action distinguishes CRB-913 from many existing obesity treatments that typically require longer periods to show meaningful weight reduction.

CRB-913 represents a potentially groundbreaking approach to obesity treatment as a non-incretin daily oral small molecule. Unlike popular GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) that require injection, CRB-913 offers the convenience of oral administration while targeting different biological pathways.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Implications and Treatment Landscape

The global obesity treatment market continues expanding rapidly, driven by rising obesity rates and increased recognition of obesity as a chronic disease requiring medical intervention. Current treatment options include lifestyle modifications, prescription medications, and bariatric surgery, but many patients struggle with side effects, cost, or accessibility issues.

The 240-patient CANYON-1 study will provide crucial dose-finding data to optimize CRB-913’s therapeutic window while minimizing potential adverse effects. This larger patient population will offer more robust safety and efficacy data compared to the initial Phase 1a study.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Next Steps and Timeline

Corbus Pharmaceuticals expects to report complete Phase 1b results in summer 2026, which will inform decisions about advancing to Phase 2 trials. The company’s focus on developing CRB-913 as both a weight loss and long-term weight management solution addresses a critical unmet medical need, as maintaining weight loss often proves more challenging than initial weight reduction.

Success in CANYON-1 could position Corbus to compete in the rapidly growing obesity pharmaceutical market, potentially offering patients a new oral treatment option with a novel mechanism of action.

---

Frequently Asked Questions

What makes CRB-913 different from existing obesity drugs?

CRB-913 is a daily oral medication with a non-incretin mechanism of action, unlike popular injectable GLP-1 drugs like Ozempic. It showed nearly 3% weight loss in just 14 days during early trials.

When will CRB-913 be available for patients?

CRB-913 is still in Phase 1b trials with results expected summer 2026. If successful, it would need to complete Phase 2 and Phase 3 trials before potential FDA approval, likely several years away.

How effective is CRB-913 compared to other obesity treatments?

Early data shows nearly 3% weight loss in 14 days, which is promising for such a short timeframe. However, longer-term efficacy data from the 16-week Phase 1b study will provide better comparison to existing treatments.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
• MariTide Phase 2 obesity data show up to 20% weight loss at one year